19|0|Public
40|$|A case is {{reported}} of lipid storage myopathy in a 24 -year-old patient and her family. In {{the patient and}} an aunt, muscle biopsy disclosed intrafibrillar lipid depositions, and electron microscopy revealed lipid vesicles in the sarcolemma border. In the father, no lipid depositions were observed but electron microscopy showed alterations to mitochondria compatible with a mitochondrial myopathy. In the patient muscular biochemistry revealed a major reduction in NADH oxydase activity and in the aunt a diminished level of <b>carnitin</b> compatible with <b>carnitin</b> deficiency. The heterogeneity of these lipidic myopathies is discussed...|$|E
40|$|A 5 -year-old {{previously}} healthy boy {{was admitted}} for abdominal pain and vomiting. Physical examination showed tachypnoe (32 /min), hepatomegaly and painful palpation {{of the upper}} right abdominal quadrant. Laboratory tests were normal except for elevated ammonium (202 mcmol/l). Chest X-ray was performed, showing cardiomegaly and interstitial edema. Transthoracic echocardiography revealed dilated left cavities and LV hypertrophy together with a diffuse hypokinesia and LVEF of 30 - 40 %. Diuretics and ACE-inhibitors were introduced. At that time, the differential diagnosis for the DCM included myocarditis, congenital or genetic, metabolic or autoimmune disease. The next day, the boy underwent cardiac magnetic resonance (CMR) examination, showing a severe dilatation of the LV with an end-diastolic diameter of 50 mm and a volume of 150 ml. LVEF was 20 % with diffuse LV hypokinesia (Fig. 1). No late enhancement was present after Gadolinium injection, ruling out myocarditis. Further laboratory metabolic analysis indicated severely decreased total and free <b>carnitin</b> levels and low renal <b>carnitin</b> reabsorption, corroborating the diagnosis of primary <b>carnitin</b> deficiency (PCD). <b>Carnitin</b> substitution was initiated. The clinical condition rapidly improved. No symptoms of heart failure were present anymore. A follow-up CMR performed 9 months later confirmed the recovery. LV end-diastolic volume decreased from 150 ml to 66 ml, LVEF increased from 20 % to 55 % (Fig. 2). Late enhancement was absent after Gadolinum injection (Fig. 3). <b>Carnitin</b> {{is required for the}} transport of fatty acids from the cytosol into mitochondria during lipid breakdown. 75 % of <b>carnitin</b> is obtained from food, 25 % is endogenously synthesized. PCD is an autosomal recessive disorder resulting from impairment of a transporter activity, caused by mutation of the SLC 22 A 5 gene. Incidence is about 1 in 40 ' 000 newborns. Diagnosis is usually made at age 1 to 7. Three forms of PCD are described. In the form associated with cardiomyopathy, the disease is progressive and patient die from heart failure if not treated. Substitution of L-Carnitin leads to a dramatic improvement of disease course. This case underlines the crucial role of etiologic diagnostics in this reversible form of DCM. Early diagnostics and therapy are critical for the prognosis of the patient. This is furthermore an example of a role played by CMR in the diagnostic work-up of heart failure and its follow-up under therapy...|$|E
40|$|Re-use of {{agricultural}} drainage water and industrial wastewater {{is one of}} the adopted strategies in different countries to close the gap between water resources and water demands. Drainage and industrial wastewater contain varieties of toxic pollutants that can potentially cause hazard on humans and environment. Although adsorption techniques are considered one of the proper methods for the wastewater treatments, economic aspect is a crucial factor for the broad application of such technique. Addressing this, the thesis concerns on proposing sorbents having the potential to remove heterogeneous pollutants simultaneously, particularly taken in consideration the limited resources in developing and emerging countries, in this study exemplified for Egypt. For this purpose, natural clayey sediments as cheap and environmentally friendly materials were used in combination with various organic modifiers to produce of organically modified clayey sediments (OMCs). In contrast to the natural clayey sediments, OMCs are expected {{to have the ability to}} remove heterogeneous pollutants including anionic and cationic as well as organic and inorganic pollutants. The sorbability and desorbability characteristics of OMCs were investigated for Cd 2 + and Pb 2 + (cationic), Cr 2 O 72 - (anionic-) and metalaxyl m (MM; organic-pollutants). The basic clay materials in OMCs were naturally occurring kaolinitic (kao sediment) and bentonitic (bent sediment) clayey sediments distributed widely in Egypt. Different concentrations of the organic modifiers L-Carnitine (<b>Carnitin),</b> L Cystine dimethyl ester (Cys_ester), Methyltriphenyl-phosphonium (MTP) or Hexadecyltrimethyl-ammonium (HDTM) were employed. The modification of natural clayey sediments with organic modifiers increased the organic carbon contents of OMCs following the order <b>Carnitin</b> 50 % of the CEC of the natural bent sediments were able to remove all Cd 2 + and Pb 2 + from the solutions. However, increasing the loading concentration of Cys_ester decreased the sorption of those metal ions as compared to natural bent sediment. OMC modified with <b>Carnitin</b> at loading concentration up to 21 % of the CEC was able to remove 84 % of Cd 2 + and 100 % of Pb 2 + from the solutions but a further increase of <b>Carnitin</b> loading decreased the sorption of the metal ions. The OMCs modified with HDTM and Cys_ester were very efficient in removing Cr 2 O 72 - from the solutions and the removal increased with increasing loading concentrations of the organic modifiers. The OMCs based on bent sediments loaded with HDTM, MTP, <b>Carnitin</b> and Cys_ester at loading concentrations equal to 102, 79, 18 and 66 % of CEC of the natural bent sediments, respectively, and in addition OMC loaded with Humic acid (HA), were selected as promising sorbents to test the sorbability and desorbability of OMCs with respect to the pollutants. The sorption processes were investigated as function of the metal concentration, sorption time, the initial solution pH and the electrolyte concentration. OMCs modified with HDTM, MTP, HA and <b>Carnitin</b> showed high sorbability for Cd 2 + and Pb 2 +. However, OMCs modified with Cys_ester displayed the best sorbent for Cr 2 O 72 -. OMCs were successful to remove almost all Cd 2 +, Pb 2 + from the solutions at wide ranges of pH; 4 - 8 and 4 - 6, respectively, while the optimum for the sorption of Cr 2 O 72 - was pH 4. The Langmuir model described adequately the observed sorption data of Cd 2 + and Pb 2 + on all sorbents and Cr 2 O 72 - on OMC modified with Cys_ester better than the Freundlich model. The sorption followed the pseudo second order kinetics with the rate constants demonstrating faster sorption on OMCs with <b>Carnitin</b> and HA for Cd 2 + and Pb 2 + and faster sorption on OMCs with MTP and Cys_ester for Cr 2 O 72 -. Sorption of Cd 2 + and Pb 2 +, particularly on OMCs with <b>Carnitin</b> and HA, were decreased with increasing electrolyte concentrations. Whereas, increasing the electrolyte concentrations enhanced the sorption of Cr 2 O 72 - to OMC with Cys_ester. OMCs showed ability to release the sorbed heavy metals, which shows the potential for re-using. The presence of other solutes in the binary and ternary component systems strengthened the sorption of Cr 2 O 72 - on OMCs based bent sediments with HDTM and MTP and enhanced the sorption of MM on OMCs with Cys_ester and MTP. Competition phenomena were recorded for the sorption of Cd 2 + and MM on OMC with HDTM. No competition behaviours were observed in the sorption of the tested pollutants on OMC with Cys_ester. OMCs with HDTM, MTP and Cys_ester were able to remove Cd 2 +, Cr 2 O 72 - and MM simultaneously from the binary and ternary component systems. The results indicate the prospective application of the OMCs in the treatments of natural agricultural drainage water and industrial wastewater. In verschiedenen Ländern ist die Nutzung landwirtschaftlichen Dränagewassers und industriellem Abwasser eine etablierte Methode um die Diskrepanz zwischen Wasserressourcen und -verbrauch zu überbrücken. Diese Wasserquellen enthalten eine Vielzahl toxischer Schadstoffe die die menschliche Gesundheit sowie die Umwelt beeinträchtigen können. Auch wenn Sorptionsverfahren als für die Aufbereitung dieser Wasserquellen geeignet betrachtet werden, ist der ökonomische Faktor ausschlaggebend für den Einsatz dieser Verfahren. Die vorgelegte Arbeit beschreibt, unter Berücksichtigung der begrenzten Ressourcen in Entwicklungs- und Schwellenländern, Sorptionsmittel, die die Fähigkeit aufweisen verschiedene Schadstoffe gleichzeitig dem Wasser zu entziehen. Zur Herstellung der Sorptionsmittel wurden natürliche tonige Sedimente, als kostengünstige und umweltfreundliche Materialien, in Kombination mit verschiedenen organischen Modifikatoren verwendet um &# 8223;organisch modifizierte tonige Sedimente? (organically modified clayey sediments: OMCs) zu erzeugen. Im Vergleich zu natürlichen tonigen Sedimenten sollen OMCs die Eigenschaft aufweisen verschiedenartige organische Schadstoffe, einschließlich anionischer, kationischer, organischer und anorganischer Schadstoffe zu sorbieren. Die Sorptions- und Desorptionseigenschaften der OMCs wurden für Cd 2 +, Pb 2 + (kationisch), Cr 2 O 72 - (anionisch) and Metalaxyl -m (MM; organisch) untersucht. Die tonigen Sedimente, die zur Herstellung der OMCs verwendet wurden, sind in Ägypten natürlich vorkommende kaolinitische (kao sediment) und bentonitische (bent sediment) tonige Sedimente. Verschiedene Konzentrationen der organischen Modifikatoren L-Carnitine (<b>Carnitin),</b> L-Cystine dimethyl ester (Cys_ester), Methyltriphenyl-phosphonium (MTP) oder Hexadecyltrimethyl-ammonium (HDTM) wurden verwendet. Die organische Modifikation der natürlichen tonigen Sedimente führte zu einem ansteigendem Gehalt an organischem Kohlenstoff, der folgenden Reihenfolge entsprechend: <b>Carnitin</b> 50 % der KAK natürlicher bentonitischer Sedimente bewirkten HDTM und MTP die vollständige Entfernung von Cd 2 + and Pb 2 + aus der Lösung; allerdings führte eine erhöhte Beladung mit Cys_ester zu einer verringerten Sorption dieser Schwermetalle, verglichen mit natürlichen bentonitischen Sedimenten. OMC, welches mit einer Konzentration von bis zu 21 % <b>Carnitin</b> modifiziert wurde, entfernte 84 % des Cd 2 + und 100 % des Pb 2 + aus der Lösung, allerdings führte die weitere Erhöhung der Carnitin-Konzentration zu einer verringerten Sorption der Metalle. OMCs die mit HDTM und Cys_ester modifiziert wurden entfernten effektiv Cr 2 O 72 - aus der Lösung, und die Sorptionsrate nahm mit steigender Konzentration der Modifikatoren zu. Auf bentonitischen Sedimenten basierende OMCs, die mit HDTM-, MTP-, Carnitin- und Cys_esterkonzentrationen gleich jeweils 102, 79, 18 and 66 % der KAK natürlicher bentonitischer Sedimente beladen waren, sowie mit Huminsäure (HA) beladenes OMC, wurden als geignete Sorbenten ausgewählt um die Sorption und Desorption von Schadstoffen zu untersuchen. Die Sorptionsprozesse wurden als Funktion der Metallkonzentration, der Sorptionszeit, des Ausgangs-pH der Lösung sowie der Elektrolyt-konzentration untersucht. OMCs die mit HDTM, MTP, HA und <b>Carnitin</b> modifiziert wurden, wiesen eine hohe Sorption von Cd 2 + and Pb 2 + auf. Jedoch zeigte mit Cys_ester modifiziertes OMC die höchste Sorption von Cr 2 O 72 -. OMCs entfernten Cd 2 + und Pb 2 + fast vollständig von Lösungen mit einem pH-Bereich von 4 - 8, bzw. 4 - 6. Das Sorptionsmaxima von Cr 2 O 72 - lag bei pH 4. Das Langmuir-Model eignete sich besser als das Freundlich-Model zur Beschreibung der Sorptionsrate aller Sorbenten für Cd 2 + und Pb 2 +, sowie für die Sorption von Cr 2 O 72 - durch mit Cys_ester modifiziertes OMC. Die Sorption folgte einer Kinetik pseudo-zweiter Ordnung; die Absorptionskonstanten weisen auf eine schnellere Sorption von Cd 2 + und Pb 2 + durch OMCs mit <b>Carnitin</b> und HA, sowie auf eine schnellere Sorption von Cr 2 O 72 - durch OMCs mit MTP und Cys_ester hin. Die Sorption von Cd 2 + und Pb 2 + wurde durch höhere Elektrolyt-Konzentrationen beeinträchtigt, insbesondere für OMC mit <b>Carnitin</b> und HA, während eine eine Erhöhung der Elektrolyt-Konzentration zu einer erhöhten Sorption von Cr 2 O 72 - durch OMC mit Cys_ester führte. Des weiteren können OMCs die sorbierten Schwermetalle desorbieren, wodurch die Wiedervertbarkeit der Materialen möglich wird. Die Präsenz anderer gelöster Stoffe in Systemen mit zwei oder drei Komponenten verstärkt die Sorption von Cr 2 O 72 - durch mit HDTM und MTP modifizierten OMCs die auf bentonitischen Sedimenten basieren, und führt zu einer größeren Sorption von MM durch mit Cys_ester und MTP modifizierten OMCs. Es wurde eine Konkurrenz für die Sorption von Cd 2 + and MM durch OMC mit HDTM beobachtet, allerdings wurde keine Konkurrenz zwischen den untersuchten Schadstoffen für mit Cys_ester modifizierten OMCs beobachtet. Mit HDTM, MTP und Cys_ester modifzierte OMCs konnten simulatan Cd 2 +, Cr 2 O 72 - und MM von den Systemen mit zwei und drei Komponenten sorbieren. Die Ergebnisse deuten auf die Möglichkeit eines erfolgreichen Einsatzes organisch modifizierter toniger Sedimente für die Aufbereitung landwirtschaftlichen Dränagewassers, sowie industrieller Abwassers hin...|$|E
40|$|ABSTRACF Oral {{administration}} of 5 g of lysine to healthy male volunteers produced a marked and progressive rise in plasma trimethyllysine (TML) from 3 to 24 h after the lysine load. Urinary TML did not register a similar rise. Plasma and urinary carnitine also increased after the lysine load. A similar rise in TML or carnitine was not seen after a 5 g tryptophan load. This {{suggests that the}} effect is specific for lysine {{and is not a}} nonspecific consequence of amino acid load. Am J C/in Nuir 1987; 46 : 772 - 7. KEY WORDS Carnitine synthesis, lysine load, plasma trimethyllysine, urinary trimethyl-lysine, plasma carnitine, urinary <b>carnitin...</b>|$|E
40|$|Valproate is a {{frequently}} used antiepileptic drug. It {{is associated with}} rare but serious adverse effects like liver failure. The first symptom is impairment of the patient's well being. Isolated changes of standard laboratory liver parameters are not reliable early indicators. Thus, according to the knowledge of today, prophylactic blood screening cannot predict complications. On the contrary, clinical symptoms are the most relevant indicators of impending complications, eventually supported by laboratory findings. An abrupt withdrawal of valproate and administering <b>carnitin</b> in parallel can interrupt the otherwise fatal course of the complication and induce a subsequent recovery. At a Consensus Conference the current knowledge about early detection and therapy of the valproate-induced serious hepatotoxicity was discussed. The results regarding recommended laboratory screening, as well as diagnostic and therapeutic strategies are reported...|$|E
40|$|Ovarian cancer marker CA 125 was {{measured}} in human seminal plasma, and the concentrations ranged between 22 and 1149 U/ml, and between 39 and 4711 U/ejaculate. This very high patient-to-patient variability was {{in contrast to a}} much lower within-patient variability, which was comparable to that of other semen parameters. No significant differences in CA 125 concentration were found in seminal plasma from normospermic patients, patients with male factors, vasectomized men, and in aliquots of samples which led to a pregnancy, via artificial insemination or in-vitro fertilization. The seminal plasma CA 125 concentration was not correlated with sperm count, motility and morphology. In contrast, seminal plasma CA 125 concentrations correlated with the age of the patient (P < 0. 001) and inversely with the volume of the ejaculate (P < 0. 001). These correlations were independent of each other. CA 125 did not correlate with the prostatic marker zinc, but did do so with the seminal vesicle marker fructose and the epididymal marker <b>carnitin...</b>|$|E
40|$|This İnvestigation {{examined}} {{the effect of}} creatin and carnitine supplementation on 5 km classic and 10 km free styles race performance of competitive cross country skiers. Eighteen highly trained (12 male and 6 female) cross country skiers aged 13 - 16 years seperated into 3 equal groups. All groups participated in the 5 km classic and 10 km free races styles in Erciyes at 2200 m altitude ski center before the carnitine and creatine loading. After the race subjects were seperated into carnitine, creatine and control groups. Creatine supplementation was given with the dosege of 20 gr divided 4 times per day and carnite wasgicen with the dossage of 2 gr divided 3 times per day, for seven days. After the last race all results were analysed by repeated measure analysis of variance and SPSS statistical program. According to the study {{there were no significant}} effects of <b>carnitin</b> and creatin supplement on 5 km classic and 10 km free styles race performans as in groups. The increased performances which were reperted can be explained by 9 days aerobic, on competition course...|$|E
40|$|Abstract: Congenital heart defects with {{increased}} pulmonary blood flow (PBF) result in pulmonary endothelial dysfunction that is dependent, {{at least in}} part, on decreases in nitric oxide (NO) signaling. Utilizing a lamb model with left-to-right shunting of blood and increased PBF that mimics the human disease, we have recently shown that a disruption in carnitine homeostasis, due to a decreased carnitine acetyl transferase (CrAT) activity, correlates with decreased bioavailable NO. Thus, we undertook this study {{to test the hypothesis}} that the CrAT enzyme {{plays a major role in}} regulating NO signaling through its effect on mitochondrial function. We utilized the siRNA gene knockdown approach to mimic the effect of decreased CrAT activity in pulmonary arterial endothelial cells (PAEC). Our data indicate that silencing the CrAT gene disrupted cellular carnitine homeostasis, reduced the expression of mitochondrial superoxide dismutase-and resulted in an increase in oxidative stress within the mitochondrion. CrAT gene silencing also disrupted mitochondrial bioenergetics resulting in reduced ATP generation and decreased NO signaling secondary to a reduction in eNOS/Hsp 90 interactions. Thus, this study links the disruption of carnitine homeostasis to the loss of NO signaling observed in children with CHD. Preserving <b>carnitin...</b>|$|E
40|$|Dietary {{agents are}} {{receiving}} much attention for the chemoprevention of cancer. While curcumin {{is known to}} influence several pathways and affect tumor growth in vivo, <b>carnitin</b> and its congeners play a variety of important metabolic functions: {{are involved in the}} oxydation of long-chain fatty acids, regulate acyl-CoA levels and influence protein activity and stability by modifying the extent of protein acetylation. In this study we evaluated the efficacy of carnitines in the prevention of cancer development using the 1, 2,-dimethylhydrazine (DMH) -induced colon carcinogenesis model. We also assessed whether their combination was able to give rise to increased protection from cancer development. Mice treated with DMH were dosed orally with curcumin and/or carnitine and acylcarnitines for 20 weeks. At the end of the treatment colon samples were collected, and scored for multiple ACF and adenomas. We observed that carnitine and acyl-carnitines had same, if not higher, efficacy than curcumin alone in inhibiting the formation of neoplastic lesions induced by DMH treatment. Interestingly, the combination of curcumin and acetyl-L-carnitine was able to fully inhibit the development of advanced adenoma lesions. Our data unveil the antitumor effects of carnitines and warrant additional studies to further support the adoption of carnitines as cancer chemopreventative agents. © 2013 Wiley Periodicals, Inc...|$|E
40|$|Marine Rhodobacteraceae (Alphaproteobacteria) are {{key players}} of {{biogeochemical}} cycling, comprise up to 30 % of bacterial communities in pelagic environments {{and are often}} mutualists of eukaryotes. As 'Roseobacter clade', these 'roseobacters' {{are assumed to be}} monophyletic, but non-marine Rhodobacteraceae have not yet been included in phylogenomic analyses. Therefore, we analysed 106 genome sequences, particularly emphasizing gene sampling and its effect on phylogenetic stability, and investigated relationships between marine versus non-marine habitat, evolutionary origin and genomic adaptations. Our analyses, providing no unequivocal evidence for the monophyly of roseobacters, indicate several shifts between marine and non-marine habitats that occurred independently and were accompanied by characteristic changes in genomic content of orthologs, enzymes and metabolic pathways. Non-marine Rhodobacteraceae gained high-affinity transporters to cope with much lower sulphate concentrations and lost genes related to the reduced sodium chloride and organohalogen concentrations in their habitats. Marine Rhodobacteraceae gained genes required for fucoidan desulphonation and synthesis of the plant hormone indole 3 -acetic acid and the compatible solutes ectoin and <b>carnitin.</b> However, neither plasmid composition, even though typical for the family, nor the degree of oligotrophy shows a systematic difference between marine and non-marine Rhodobacteraceae. We suggest the operational term 'Roseobacter group' for the marine Rhodobacteraceae strains. The ISME Journal advance online publication, 20 January 2017; doi: 10. 1038 /ismej. 2016. 198...|$|E
40|$|Background and Aims: Physical {{exercise}} {{leads to}} substantial adaptive responses in skeletal muscles and plays {{a central role}} in a healthy life style. Since exercise induces major systemic responses, underlying cellular mechanisms are difficult to study in vivo. It was therefore desirable to develop an in vitro model that would resemble training in cultured human myotubes. Methods: Electrical pulse stimulation (EPS) was applied to adherent human myotubes. Cellular contents of ATP, phosphocreatine (PCr) and lactate were determined. Glucose and oleic acid metabolism were studied using radio-labeled substrates, and gene expression was analyzed using real-time RT-PCR. Mitochondrial content and function were measured by live imaging and determination of citrate synthase activity, respectively. Protein expression was assessed by electrophoresis and immunoblotting. Results: High-frequency, acute EPS increased deoxyglucose uptake and lactate production, while cell contents of both ATP and PCr decreased. Chronic, low-frequency EPS increased oxidative capacity of cultured myotubes by increasing glucose metabolism (uptake and oxidation) and complete fatty acid oxidation. mRNA expression level of pyruvate dehydrogenase complex 4 (PDK 4) was significantly increased in EPS-treated cells, while mRNA expressions of interleukin 6 (IL- 6), cytochrome C and <b>carnitin</b> palmitoyl transferase b (CPT 1 b) also tended to increase. Intensity of MitoTrackerHRed FM was doubled after 48 h of chronic, low-frequency EPS. Protein expression of a slow fiber type marker (MHCI) was increased in EPS-treated cells...|$|E
40|$|Physical {{exercise}} {{leads to}} substantial adaptive responses in skeletal muscles and plays {{a central role}} in a healthy life style. Since exercise induces major systemic responses, underlying cellular mechanisms are difficult to study in vivo. It was therefore desirable to develop an in vitro model that would resemble training in cultured human myotubes. Electrical pulse stimulation (EPS) was applied to adherent human myotubes. Cellular contents of ATP, phosphocreatine (PCr) and lactate were determined. Glucose and oleic acid metabolism were studied using radio-labeled substrates, and gene expression was analyzed using real-time RT-PCR. Mitochondrial content and function were measured by live imaging and determination of citrate synthase activity, respectively. Protein expression was assessed by electrophoresis and immunoblotting. High-frequency, acute EPS increased deoxyglucose uptake and lactate production, while cell contents of both ATP and PCr decreased. Chronic, low-frequency EPS increased oxidative capacity of cultured myotubes by increasing glucose metabolism (uptake and oxidation) and complete fatty acid oxidation. mRNA expression level of pyruvate dehydrogenase complex 4 (PDK 4) was significantly increased in EPS-treated cells, while mRNA expressions of interleukin 6 (IL- 6), cytochrome C and <b>carnitin</b> palmitoyl transferase b (CPT 1 b) also tended to increase. Intensity of MitoTracker®Red FM was doubled after 48 h of chronic, low-frequency EPS. Protein expression of a slow fiber type marker (MHCI) was increased in EPS-treated cells. Our results imply that in vitro EPS (acute, high-frequent as well as chronic, low-frequent) of human myotubes may be used to study effects of exercise...|$|E
40|$|L-Carnitin ist notwendig für der Translokation langkettiger Fettsäuren über die innere Mitochondrienmembran und somit für die anschließende Energiegewinnung durch b-Oxidation. <b>Carnitin</b> selbst wird über den kürzlich klonierten plasmamembranständigen hochaffinen Na+/Carnitin-Cotransporter hOCTN 2 in die Zelle transportiert. Dieser Transporter gehört zu der Familie der organischen Kationentransporter (OCT). Ziel der vorliegenden Arbeit war eine funktionelle und pharmakologische Charakterisierung von hOCTN 2 mittels Two-Electrodes-Voltage-Clamp und Flux-Messungen an hOCTN 2 -injizierten Xenopus laevis Oozyten. Der L-Carnitintransport durch hOCTN 2 war Na+-abhängig, elektrogen und sättigbar. Die Halbsättigungskonzentration für Natrium betrug 0. 3 ± 0. 1 mM bei - 60 mV. Es zeigte sich eine leichte Stereospezifität für L-Carnitin mit einem Km-Wert von 4. 9 ± 0. 3 µM für L-Carnitin und einem Km-Wert von 98. 3 ± 38. 0 für D-Carnitin. Weiterhin wurde der Einfluß des extra- und intrazellulären pH-Wertes auf die L-Carnitin-induzierten Ströme untersucht. Es fand sich eine Abnahme der L-Carnitin-induzierten Ströme bei Azidifizierung des extrazellulären Mediums. Eine intrazelluläre Ansäuerung mit Bicarbonat bewirkte eine signifikante Hemmung des Carnitinstromes um 22. 3 ± 4. 5 Im Gegensatz zu anderen Mitgliedern der OCT-Familie scheint hOCTN 2 also ein hochaffiner Na+/Carnitin-Cotransporter zu sein, ohne Beteiligung eines Symport- oder Antiportmechanismus für andere Kationen als Natrium. hOCTN 2 zeigte nur kleine Ströme für klassische Substrate anderer OCTs wie Cholin oder TEA, während sich bei rOCT 1 und hOCT 2 keine Ströme durch <b>Carnitin</b> induzieren ließen. Der hOCTN 2 vermittelte L-Carnitintransport ließ sich durch einige Pharmaka hemmen, die ein sekundäres Carnitinmangelsyndrom auslösen können. Die stärksten Hemmstoffe waren Emetin, Verapamil, Quinidin, Betain und Cystein. Das Antiepileptikum Valproinsäure zeigte keinen nennenswerten inhibitorischen Effekt, was auf einen anderen HemmechL-Carnitine is {{essential}} for the translocation of acyl-carnitine into the mitochondria for &# 946;-oxidation of long-chain fatty acids. It is taken up into the cells by the recently cloned Na+-driven carnitine organic cation transporter OCTN 2. Here we expressed hOCTN 2 in Xenopus laevis oocytes and investigated with two-electrode voltage-clamp and flux measurements its functional and pharmacological properties as a Na+-carnitine cotransporter. L-carnitine transport was electrogenic. The L-carnitine-induced currents were voltage and Na+ dependent, with half-maximal currents at 0. 3 ± 0. 1 mM Na+ at - 60 mV. Furthermore, L-carnitine-induced currents were pH dependent, decreasing with acidification. In contrast to other members of the organic cation transporter family, hOCTN 2 functions as a Na+ - coupled carnitine transporter. Carnitine transport was stereoselective, with an apparent Michaelis-Menten constant (Km) of 4. 8 ± 0. 3 &# 956;M for L-carnitine and 98. 3 ± 38. 0 &# 956;M for D-carnitine. The substrate specificity of hOCTN 2 differs from rOCT- 1 and hOCT- 2 as hOCTN 2 showed only small currents with classic OCT substrates such as choline or tetraethylammonium; by contrast hOCTN 2 mediated transport of betaine. hOCTN 2 was inhibited by several drugs known to induce secondary carnitine deficiency. Most potent blockers were the antibiotic emetine and the ion channel blockers quinidine and verapamil. The apparent IC 50 for emetine was 4. 2 ± 1. 2 &# 956;M. The anticonvulsant valproic acid did not induce a significant inhibition of carnitine transport, to a different mode of action. In summary, hOCTN 2 mediates electrogenic Na+-dependent stereoselective high-affinity transport of L-carnitine and Na. HOCTN 2 displays transport properties distinct from other members of the OCT family and is directly inhibited by several substances known to induce systemic carnitine deficiency...|$|E
40|$|Fettsäuren haben vielfältige Funktionen im Organismus. Sie sind der wichtigste Energieträger des menschlichen Körpers. Fettsäuren sind Bestandteil menschlicher Membranen und Ausgangspunkt für die Biosynthese biologisch aktiver Substanzen. Der Abbau der Fettsäuren und deren energetische Verwertung geschieht im Mitochondrium, dem Ort der ß-Oxidation. Hierfür werden die Fettsäuren mit Hilfe des aus 3 Enzymen bestehenden Carnitin- Palmitoyltransferase-Systems aus dem Cytosol in das Mitochondrium transportiert. Dazu werden langkettige Fettsäuren durch die Acyl-CoA-Synthetase aktiviert und - an <b>Carnitin</b> gebunden - in das Innere der Mitochondrien geschleust. Die Carnitin-Palmitoyltransferase 1 (CPT 1) ist an der Innenseite der äußeren Mitochondrienmembran gebunden und katalysiert die Kopplung von L-Carnitin an die aktivierte Fettsäure unter Freisetzung von Coenzym A. Das so enstandene Acyl-Carnitin passiert mit Hilfe der Carnitin- Acylcarnitin-Translokase (CAC) die innere Mitochondrienmembran. An der Innenseite der mitochondrialen Innenmembran überträgt die Carnitin-Palmitoyltransferase 2 (CPT 2) den Fettsäurerest des Acyl-Carnitins auf Coenzym A, wobei Acyl-CoA und freies <b>Carnitin</b> entsteht. Nun schließt sich der Abbau der Fettsäuren, die ß-Oxidation an. Ziel dieser Arbeit war die Untersuchung der Carnitin-Palmitoyltransferase 1 in Entzündungszuständen und die Klärung der Frage, ob Stickstoffmonoxid (NO) einen Einfluss auf die Regulation der CPT 1 hat. Darüberhinaus wurde die Wirkung von PPAR-a (peroxisome proliferator-activated receptor-a) auf die induzierbare NO-Synthase (iNOS) und damit die Generierung von NO untersucht. Die Experimente wurden an Ratten-Mesangiumzellen durchgeführt. Interleukin 1 ß stimuliert die Expression der CPT 1 auf mRNA und Protein-Ebene. In Kombination mit Palmitat und <b>Carnitin</b> konnte die Expression der CPT 1 signifikant gesteigert werden. Es konnte gezeigt werden, dass NO ein potenter Stimulator der Carnitin-Palmitoyltransferase 1 ist. Mesangiumzellen, die mit NO und IL- 1 ß kombiniert stimuliert wurden, zeigten bereits nach 2 Stunden eine Reduktion der Expression auf das Niveau der unstimulierten Kontrolle. IL- 1 ß und L-NG-Monomethyl- Arginin (L-NMMA), ein spezifischer Inhibitor der induzierbaren NO-Synthase erhöhen die CPT- 1 Expression. In einem Tiermodell des hämorrhagischen Schocks wurde die CPT 1 mRNA Expression signifikant reprimiert, die Gabe eines iNOS-Inhibitors konnte diese Herunterregulierung wieder aufheben. Stickstoffmonoxid spielt eine sehr wichtige Rolle bei Entzündungsreaktionen. Die induzierbare NO-Synthase ist das verantwortliche Enzym für die Produktion von großen Mengen NO. Die NO-Synthase (NOS) katalysiert die Umsetzung von L-Arginin unter Sauerstoffverbrauch in Citrullin unter Entstehung von NO. Der Mechanismus, der für einen verzögerten Beginn der Transkription von vier Stunden mit darauf folgender mehr als 24 -stündiger immenser mRNA Synthese. nach einer Zytokinstimulation verantwortlich ist, ist noch nicht verstanden. Der Untersuchung dieser verzögerten und anhaltenden iNOS Expression lag die Hypothese zugrunde, dass die Zytokin-induzierte iNOS Transkription zuerst durch NFkB und C/EBP Transkriptionsfaktoren ausgelöst und anschließend durch andere Mediatoren verlängert und verstärkt wird. Zur Identifizierung möglicher regulatorischer Elemente wurden 4, 5 kb der 5 ' flankierenden Region des iNOS Promotors aufwärts des Transkriptionsstarts kloniert. Mittels Analyse der DNase 1 hypersensitiven Bereiche der 5 'Region des iNOS Gens konnten zwei hypersensitive Stellen identifiziert werden (DHS 1 : 1300 bp; DHS 2 : 3000 bp). Beide Stellen enthalten {{putative}} PPAR-Bindestellen. Zur weiteren Untersuchung wurde die Wirkung des PPAR-a auf die iNOS analysiert. Dabei konnte gezeigt werden, dass der PPAR-a Agonist Wy 14643 in Kombination mit IL- 1 ß in der Lage ist sowohl Aktivität, Protein als auch die mRNA der iNOS zu steigern. Transfektionsexperimente mit deletierten und mutierten iNOS Promotorfragmenten zeigten, dass DHS 1 das für die Stimulation verantwortliche DNA Fragment enthält. Mittels Elektrophoretic-Mobility-Shift-Assay konnte gezeigt werden, dass der PPAR-a Agonist Wy 14643 die Bindung des PPA-Rezeptors an DHS 1 verstärkt. Fatty acids have diverse {{functions in}} the organism. They {{are the most important}} source of energy of the human body. Fatty acids are components of human membranes and they initiate the biosynthase of biologically active substances. The decomposition of fatty acids and their energetic utilization takes place in the mitochondrium, the place of ß-oxidation. For this process the fatty acids are transported from the cytosol into the mitochondrium {{with the help of the}} <b>carnitin</b> Carnitine-palmitoyltransferase (CPT) system. During this process the long-chained fatty acids are activated by acyl-CoA-Synthetase and - linked to carnitine - transported into the inner mitochondrial membrane. Carnitine-palmitoyltransferase 1 (CPT 1) is linked to the outer mitochondrial membrane and catalyses the attachment of L-carnitine to the activated fatty acid while setting free the Coencime A. The new acylcarnitine molecule is transported into the mitochondria by the acylcarnitine translocase (CAC) in exchange for carnitine. Carnitine-palmitoyltransferase 2 (CPT 2) transfers the rest of the fatty acids of the acylcarnitine onto the CoA generating free carnitine. After that the ß-oxidation follows. The aim of this work was to investigate the Canitine-palmitoyltransferase 1 on inflammatory situations and to answer the question, if nitric oxide (NO) influences the regulation of CPT 1. Furthermore, the effect of PPAR-a (peroxisome proliferatoractivated receptor-a) on the inducible NO-synthase (iNOS) was investigated and with this the formation of NO. The experiments were done with mesangial cells of rats. Interleukin 1 ß stimulates the expression of CPT 1 on the mRNA and protein level. Palmitate and carnitine together can significantly increase the expression of CPT 1. The results have shown that NO is an potent stimulator of Carnitinpalmitoyltransferase 1. Mesangial cells which had been stimulated with NO and IL- 1 ß showed a reduction of the expression of CPT 1 on (unstimulated) controll niveau already after 2 hours. IL- 1 ß and L-NG-Monomethyl-Arginine (L-NMMA), a specific inhibitor of the inducible NO-synthase, increase the CPT 1 expression. For in vivo relevance I made experiments in an animal modell of haemorrhagic shock, where the CPT 1 mRNA expression was significantly repressed. The addition of an iNOS-inhibitor could reverse this downregulation. Nitric oxide plays a very important role in inflammatory reactions. The inducible NO-synthase is the encime responsible for the production of great amounts of NO. The NO-synthase (NOS) catalyses the change of L-arginine into citrulline using oxygen and generating NO. We still do not understand the mechanism that is responsible for a four-hour delay of the beginning of the transcription followed by an immense twentyfour-hour lasting mRNA synthesis and after a cytocin stimulation. The investigation of this delayed and permanent iNOS expression was based on the assumption that at first the cytokin induced iNOS transcription is triggered off by NFkB and C/EBP transcriptional factors and then being extended and enhanced by other mediators. To identify possible regulatory DNA elements, 4, 5 kb of the 5 'flanking region of the iNOS promoter has been cloned alongside the start of the transcription in an upwardly direction. By analysing of the the Dnase 1 -hypersensitive areas of the 5 'region of the iNOS gene two hypersensitive parts could be identified (DHS 1 : 1300 bp; DHS 2 : 3000 bp). Both regions contain putative binding sites for the peroxisome proliferator-activated receptor (PPAR). For further investigation the effect of different PPAR-a agonists on iNOS expression were analysed. It was possible to prove that the PPAR-a agonist Wy 14643 in combination with IL- 1 ß is able to increase its activity, protein and, as well, the mRNA of iNOS. Transfectional experiments with deleted or mutated iNOS promotor fragments showed that DHS 1 contains the DNA fragment responsible for the stimulation. Using electrophoretic mobility shift assay proved that the PPAR-a agonist Wy 14643 enhances the link of the PPA-Receptor onto DHS 1...|$|E
40|$|Background: To {{evaluate}} {{the effects of}} an eye drop containing eleidosin and carnitine in patients suffering from primary open-angle glaucoma (POAG) and ocular discomfort syndrome secondary to a chronically treated with eye drops containing benzalkonium chloride (BAK) as preservative. The dry eye disease {{was defined as a}} multifactorial drop disease concerning tears and ocular surface which brings to discomfort symptoms and visual disorders with potential damage to the ocular surface. Several studies underlined the beneficial effects of secretagogues drugs, such as eledoisin. It is a neuro-peptide extracted from the salivary glands of some shellfishes. Recently it has been also showed the protective role of carnitine in respect of the ocular surface exposed to the tear film hyperosmolarity. Materials and methods: This randomized double-blind pilot study has been evaluated by lubricant eye drop solutions containg eledoisin and carnitine in 40 patients with ocular discomfort syndrome secondary to POAG, since that the patients were chronically treated with eye drops which decrease eye pressure and contain BAK as preservative. The subjects filled out a questions form concerning the severity of the symptoms and their impact on daily activities. Subsequently Fluorescein Break-Up Time (FBUT), Schirmer Test 1 (ST), and Ocular Protection Index (OPI) were measured at baseline and after 15 days of treatment. Results: At the end of therapy it was possible to match the beneficial effects of eye drops with <b>carnitin,</b> taurine, sodium hyaluronate and eledoisin. In fact, after 15 days of treatment, patients of group 1 showed a decrease of approximately 50 % concerning the severity of symptoms and a significant improvement of the tests valued. Conclusion: In summary, lubricant eye drops that restore physiological hosmolarity and stimulate tear production represent a promising strategy for dry eye syndrome...|$|E
40|$|Background and Aims Physical {{exercise}} {{leads to}} substantial adaptive responses in skeletal muscles and plays {{a central role}} in a healthy life style. Since exercise induces major systemic responses, underlying cellular mechanisms are difficult to study in vivo. It was therefore desirable to develop an in vitro model that would resemble training in cultured human myotubes. Methods Electrical pulse stimulation (EPS) was applied to adherent human myotubes. Cellular contents of ATP, phosphocreatine (PCr) and lactate were determined. Glucose and oleic acid metabolism were studied using radio-labeled substrates, and gene expression was analyzed using real-time RT-PCR. Mitochondrial content and function were measured by live imaging and determination of citrate synthase activity, respectively. Protein expression was assessed by electrophoresis and immunoblotting. Results High-frequency, acute EPS increased deoxyglucose uptake and lactate production, while cell contents of both ATP and PCr decreased. Chronic, low-frequency EPS increased oxidative capacity of cultured myotubes by increasing glucose metabolism (uptake and oxidation) and complete fatty acid oxidation. mRNA expression level of pyruvate dehydrogenase complex 4 (PDK 4) was significantly increased in EPS-treated cells, while mRNA expressions of interleukin 6 (IL- 6), cytochrome C and <b>carnitin</b> palmitoyl transferase b (CPT 1 b) also tended to increase. Intensity of MitoTracker®Red FM was doubled after 48 h of chronic, low-frequency EPS. Protein expression of a slow fiber type marker (MHCI) was increased in EPS-treated cells. Conclusions Our results imply that in vitro EPS (acute, high-frequent as well as chronic, low-frequent) of human myotubes may be used to study effects of exercise. This work was funded by the University of Oslo, Oslo University College, the Norwegian Diabetes Foundation, the Freia Chocolade Fabriks Medical Foundation and the Anders Jahre’s Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript...|$|E
40|$|The {{objectives}} {{of the present study}} were to evaluate the effect of conjugated linoleic acid (CLA t 10, c 12, C 18. 2). linolenic acid (C 18 : 3) and docosahexaenoic acid (DHA. C 22. 6) supplementation on in vitro bovine embryo development, embryo survival after cryopreservation, gene expression and AMPK alpha phosphorylation Control groups with modified synthetic oviduct fluid (mSOF) +/- 100 mu M beta-mercaptoethanol (beta-ME) were performed. The effects of co-culture with bovine oviduct epithelial cell (Boec) monolayers, serum supplementation and embryo development in the ewe oviduct, on gene expression were also examined. Experiments 1 and 2 a lower d 7 embryo survival was found with 100 mu M C 22 6 and 100 mu M C 18 2 supplementation compared to 1 mu M C 22. 6 and 100 mu M beta-ME supplementation (P < 0 05) C 18 3 supplementation had no effect on cl 7 embryo survival, but 100 mu M C 18. 3 increased d 8 embryo survival compared to 100 mu M beta-ME supplementation (P < 0 05) Experiments 3 and 4 stearoyl-CoA desaturase 1 (SCD 1) and sterol regulatory element-binding transcription factor 1 (SREBP 1) mRNA decreased after 10 mu M C 22. 6 supplementation compared to all other supplementations (P < 0 05) A lower fatty acid desaturase 2 (FADS 2) transcript level was found with 100 mu M C 18 : 2. 10 mu M C 22 : 6 and 10 mu M C 18 : 3 supplementations compared to groups without fatty acid supplementation (P < 0. 05). Acetyl-CoA-carboxylase (ACC), fatty acid synthase (FAS), adipose differentiation-related protein (ADRP). acyl-CoA synthetase long-chain family member 1 (ACSL 1), diacylglycerol O-acyltransferase 1 (DGAT 1), <b>carnitin</b> palmitoyltransferase-II (CPT-II) mRNAs expression and AMPKa phosphorylation were not modified with PUFA supplementation Experiment 5. SCD 1 and FAS mRNA decrease in Boec group compared to serum supplementation, as SCD 1 mRNA in ewe oviduct group (P < 0 05) In conclusion, this study showed that a PUFA supplementation with C 18 : 2, C 18 3 or C 22 6 in bovine culture development for 6 days and co-culture with Boec down-regulate mRNA expression of proteins involved in lipid metabolism in d 7 - 8 embryo (SCD 1 and FADS 2 desaturases), probably through SREBP 1 mRNA regulation after 10 mu M C 22. 6 supplementation, indicating a modification of saturated/unsaturated fatty acid balance in bovine blastocyst...|$|E
40|$|SummaryObjectiveTo {{investigate}} {{the potency of}} selective agonists of peroxisome proliferators-activated receptors' (PPAR) isotypes (α, β/δ or γ) to modulate the stimulating effect of transforming growth factor-β 1 (TGF-β 1) on proteoglycans' (PGs) synthesis in chondrocytes. MethodRat chondrocytes embedded in alginate beads and cultured under low serum conditions were exposed to TGF-β 1 (10 ng/ml), alone or {{in combination with the}} following agonists: Wy 14643 for PPARα, GW 501516 for PPARβ/δ, rosiglitazone (ROSI) for PPARγ, in {{the presence or absence of}} PPAR antagonists (GW 6471 for PPARα, GW 9662 for PPARγ). PGs' synthesis was evaluated by radiolabelled sulphate incorporation and glycosaminoglycans' (GAGs) content by Alcian blue staining of beads and colorimetric 1. 9 dimethyl-methylene blue assay after beads' solubilization. Phosphorylation of Extracellular Signal-related Kinase 1 / 2 (ERK 1 / 2), Smad 2 / 3 and p 38 -MAPK was assessed by Western Blot and production of prostaglandin E 2 (PGE 2) by Enzyme immuno-assay (EIA). Levels of mRNA for PPAR target genes [acyl-CoA oxidase (ACO) for PPARα; mitochondrial <b>carnitin</b> palmitoyl transferase- 1 (CPT- 1) for PPARβ/δ and adiponectin for PPARγ], aggrecan, TGF-β 1 and genes controlling GAGs' side chains' synthesis were quantified by real time polymerase chain reaction and normalized over RP 29 housekeeping gene. ResultsACO was selectively up-regulated by 100 μM of Wy 14643, CPT- 1 by 100 nM of GW 501516 and adiponectin by 10 μM of ROSI without cell toxicity. TGF-β 1 increased PGs' synthesis by four-fold, GAGs' content and deposition by 3. 5 -fold and six-fold, respectively, while inducing aggrecan expression around 10 -fold without modifying mRNA levels of GAGs' controlling enzymes. PPAR agonists inhibited the stimulating effect of TGF-β 1 by 24 – 44 % on PGs' synthesis and over 75 % on aggrecan, GAGs' content and deposition with the following rank order of potency: ROSI>GW 501516 ≥Wy 14643. TGF-β 1 -induced phosphorylation of Smad 2 / 3 and ERK 1 / 2 was reduced by ROSI over GW 501516 but not by Wy 14643 whereas stimulated PGE 2 production was inhibited by Wy 14643 over GW 501516 but not by ROSI. The effect of PPAR agonists on PPAR target genes and TGF-β 1 -induced aggrecan expression was reversed selectively by PPAR antagonists. ConclusionIn chondrocytes' beads, PPAR agonists reduced the stimulating effect of TGF-β 1 on PGs by inhibiting TGF-β 1 -induced aggrecan expression in an isotype-selective manner. Thus, PPAR agonists could be deleterious in situation of cartilage repair although being protective in situation of cartilage degradation...|$|E
40|$|Nuclear receptors (NRs), {{most notably}} the {{constitutive}} androstane receptor (CAR) and the pregnane X receptor (PXR), regulate the transcription of several drug metabolizing enzymes and transporters (DMET) and thus represent important regulators of drug metabolism in the liver. Accordingly, the ligand dependent activation of these NRs by drugs and other xenobiotics contributes to the intra- and inter-individual variability of the drug detoxifying system. CAR and PXR were further shown to regulate the transcription of key enzymes involved in lipid and glucose metabolism. The NR peroxisome proliferator-activated receptor alpha (PPARa), a key regulator of fatty acid catabolism and target of lipid lowering fibrates, was recently identified as a direct regulator of cytochrome P 450 3 A 4 (CYP 3 A 4) and also potentially of other DMET genes. In this respect, CAR, PXR and PPARa are determinants of an overlapping number of liver functions including drug metabolism and energy homeostasis and are therefore associated with adverse drug reactions as well as liver disease like steatosis. Until now {{there have been no}} comparative studies investigating the transcriptomes of CAR, PXR and PPARa in humans. Therefore, a major focus {{of this study was to}} assess the genome-wide transcriptional changes provoked by these NRs in primary human hepatocytes (PHHs). To investigate human liver-specific gene expression and its regulation PHHs represent the most suitable available in vitro cell system. To identify the CAR-, PXR- and PPARa-specific genome-wide expression changes, hepatocyte cultures from six individual donors were treated with the prototypical ligands for CAR (CITCO), PXR (rifampicin) and PPARa (WY- 14643) as well as DMSO (vehicle control). Afterwards, the mRNA expression in these samples was determined utilizing Affymetrix® microarrays. The obtained expression data were statistically evaluated to identify the genes that showed a differential expression in response to the agonist treatments and to investigate to which metabolic functions these genes contribute. The results of these experiments confirmed that CAR, PXR and PPARa regulated a highly overlapping but distinct set of genes coding for DMET. For example, according to KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analyses expression of 10 DMET genes were shown to be regulated by all three NRs, whereas other DMET genes responded exclusively to the activation of one of the NRs. In addition several DMET related genes previously not shown to be regulated by CAR [like CYP 2 E 1, sulfotransferase 1 B 1 (SULT 1 B 1), UDP-glucuronosyltransferase 2 B 4 (UGT 2 B 4) and cytochrome P 450 reductase (POR) ], PXR [like CYP 2 E 1, alcohol dehydrogenases (ADHs), flavin containing monooxygenase 5 (FMO 5) and glutathione peroxidase 2 (GPX 2) ] or PPARa like UBT 2 B 4, ADH 1 s and FMO 5) were identified to respond to the respective agonists. For PXR and CAR, this extends the list of genes by which these NRs influence drug metabolism and potentially contribute to drug-drug interactions (DDIs). The results obtained further specify the role of PPARa as a regulator of drug metabolism in vitro by increasing expression of, e. g., CYP 3 A 4, 2 B 6, 2 C 8 and UGT 1 A 1, thus pointing to a potential role of PPARa in adverse drug reactions in vivo. Furthermore, several genes coding for proteins involved in energy homeostasis, were identified as differentially expressed in response to PXR activation [e. g., pyruvate dehydrogenase kinase 4 (PDK 4), glycogen synthase 2 (GYS 2), carnitine palmitoyltransferase 2 (CPT 2) ], where such a relation was not reported so far. These results further expanded the knowledge of how PXR potentially impact fatty acid catabolism, gluconeogenesis and lipid de novo synthesis and provide interesting starting points to investigate how PXR activation contributes to altered glucose and lipid levels or disease like hepatic steatosis. Besides ligand-dependent regulation of nuclear receptors, post-translational modification has also been shown to influence the activity of liver-enriched NRs and expression of their target genes. In this context, protein kinase A (PKA) had been shown to repress CYP 3 A 4 expression via PXR in a species-dependent manner, whereas the influence of PKA on the expression of other DMET genes had not been investigated in detail so far. The second part of this work therefore investigated the impact of PKA activation on the expression and activity of important drug metabolizing enzymes in a PXR- as well as a CAR-dependent manner. In this work PKA activation in primary human hepatocytes was identified as a determinant of drug metabolism in vitro by repressing PXR- and CAR-mediated or reducing basal expression and activity of CYP 1 A 1, CYP 2 B 6, CYP 2 C 8 and CYP 3 A 4, but also expression of ATP-binding cassette B 1 (ABCB 1) and UGT 1 A 1. Using reporter gene assays, these observed effects could be linked to PKA-mediated repression of PXR and CAR activity that may involve phosphorylation of these NRs. It could be further shown that expression of DMET genes was also repressed by the fasting hormone glucagon, a physiologically relevant activator of PKA signaling, which was not investigated in humans so far. Due to the promiscuous ligand-specificity of PXR, which includes numerous compounds, drug treatment often leads to PXR activation, even with so-called “natural” compounds like St. John’s wort (SJW). It would thus be highly desirable to develop strategies in drug development to assess or circumvent the activation of NRs without compromising the pharmacological effects. Therefore, the last part of this work consists of an in vitro study to investigate synthetic acylated phloroglucinols, designed as substitutes for hyperforin, regarding their potential to activate PXR. Hyperforin the major active constituent of the plant SJW used to treat depressions was shown to exert its antidepressant properties via indirect inhibition of serotonin reuptake by selectively activating the canonical transient receptor potential channel 6 (TRPC 6). In addition, hyperforin is associated with clinically relevant drug-drug interactions in patients that had taken SJW concomitantly with other drugs due to potent activation of the nuclear receptor PXR by hyperforin. The phloroglucinol derivatives investigated in this thesis had previously been evaluated for their bioactivity. It had been reported that five of the nine synthetic acylated phloroglucinols activate TRPC 6 with similar potency as hyperforin. In this work, all these nine synthetic phloroglucinol derivatives were investigated in comparison to hyperforin and rifampicin for their potential to activate PXR. Hyperforin and rifampicin treatment of HepG 2 cells co-transfected with a human PXR expression vector and a CYP 3 A 4 promoter reporter construct resulted in potent PXR-dependent induction, while all TRPC 6 -activating compounds failed to show any PXR activation or to antagonize rifampicin-mediated CYP 3 A 4 promoter induction. Hyperforin and rifampicin treatment of primary human hepatocytes resulted in highly correlated induction of PXR target genes, whereas treatment with the phloroglucinol derivatives elicited moderate gene expression changes that only weakly correlated to those of rifampicin treatment. The herein observed lack of PXR activation by the TRPC 6 activating phloroglucinols was further supported by in silico pharmacophore modeling that did not indicate potent agonist or antagonist interactions for the TRPC 6 activating derivatives and docking studies that suggested interaction of only one of these compounds. These in silico studies performed by Prof. Sean Ekins are published together with the results presented in this work (Kandel et al., 2014). This approach shows that strategies avoiding PXR activation are conceivable in drug development in order to prevent DDIs and improve drug safety. Taken together, these results further increase the number of genes by which CAR, PXR, and PPARa contribute to the regulation of drug metabolism and energy homeostasis. Moreover it was demonstrated that the PKA, which is involved in the transduction of the effects of, e. g., the hormone glucagon, represents a determinant of the drug detoxifying system in humans. Furthermore, a strategy could be presented, taking the example of the hyperforin derivates, which can be used to investigate and avoid DDIs in drug development. Such information will become imperative in future personalized medicine and the ever-present polypharmacy in order to handle intra- and inter-individual variability and to minimize drug failure or drug-drug interactions. Kernrezeptoren, allen voran der Constitutive Androstane Receptor (CAR) und der Pregnane X Receptor (PXR), regulieren die Transkription zahlreicher Arzeimittel- metabolisierender Enzyme und Transporter (engl. drug metabolizing enzymes and transporters / DMET) und stellen damit wichtige Regulatoren der Entgiftungs-prozesse in der Leber dar. Folglich trägt die Liganden-abhängige Aktivierung dieser Rezeptoren, durch Arzneimittel und andere körperfremde Stoffe, zur intra- und inter-individuellen Variabilität des Arzneimittelstoffwechsels bei. CAR und PXR sind zudem in die Regulation des Fett- und Glukosestoffwechsels involviert. Auch für den Kernrezeptor Peroxisome Proliferator-activating Receptor Alpha (PPARa), ein Schlüsselregulator des Fettsäure-Abbaus und Ansatzpunkt von Fibraten, wurde kürzlich gezeigt, dass dieser die Expression von Cytochrom P 450 3 A 4 (CYP 3 A 4) direkt reguliert und darüber hinaus mit der Regulation weiterer wichtiger DMET-Gene assoziiert ist. In diesem Zusammenhang stellen CAR, PXR und PPARa wichtige Determinanten von Leberfunktionen wie Arzneimittel-Metabolismus und Energie-homöostase dar und stehen dadurch in Verbindung mit Arzneimittelnebenwirkungen, sowie Lebererkrankungen, wie beispielsweise Steatose. Bis jetzt gibt es keine vergleichenden Studien, welche die Transkriptome der Kernrezeptoren CAR, PXR und PPARa im Menschen untersucht haben. Deshalb war ein Hauptaspekt dieser Arbeit, die genomweiten transkriptionellen Veränderungen, welche durch diese Kernrezeptoren in humanen Leberzellen hervorgerufen werden, zu untersuchen. Diese Untersuchungen wurden mit primären humanen Hepatozyten durchgeführt, da diese Zellen das geeignetste verfügbare Zell-Modell zur Untersuchung der leberspezifischen Gen-Expression und deren Regulation darstellen. Um die CAR-, PXR- und PPARa-spezifischen, genomweiten Expressions-änderungen zu bestimmen, wurden Hepatozyten-Kulturen von sechs verschiedenen Spendern mit den prototypischen Liganden für CAR (CITCO), PXR (Rifampicin) und PPARa (WY- 14643), sowie mit DMSO, der Vehikel-Kontrolle, behandelt. Im Folgenden wurde die mRNA-Expression in diesen Proben mittels Affymetrix® Microarrays bestimmt. Die Expressions-Daten wurden statistischen Analysen unterzogen, um die Gene zu identifizieren, die eine signifikant veränderte Expression durch die Agonisten-Behandlungen zeigten; des Weiteren wurde untersucht, mit welchen metabolischen Funktionen diese Gene assoziiert sind. Die so gewonnenen Resultate bestätigten, dass CAR, PXR und PPARa unterschiedliche, aber dennoch teilweise überlappende Gruppen von DMET-Genen regulieren. Durch KEGG- (Kyoto Encyclopedia of Genes and Genomes) Pathway-Analysen wurde beispielsweise gezeigt, dass eine Gruppe von zehn DMET-Genen gleichermaßen durch CAR, PXR und PPARa reguliert wurden, wohingegen die Expression weiterer DMET-Gene exklusive durch die Aktivierung einer der drei Rezeptoren beeinflusst wurde. Für eine Reihe dieser Gene wurde hierbei eine Regulation durch die Rezeptoren CAR [z. B. CYP 2 E 1, Sulfotransferase 1 B 1 (SULT 1 B 1), UDP-Glucuronosyltransferase 2 B 4 (UGT 2 B 4) und Cytochrom P 450 Reductase (POR) ], PXR z. B. CYP 2 E 1, Alkohol Dehydrogenasen (ADHs), Flavin-abhängige Monooxygenase 5 (FMO 5) und Glutathion Peroxidase 2 (GPX 2) ] und PPARa [z. B. UBT 2 B 4, ADH 1 s und FMO 5] erstmals gezeigt. Für CAR und PXR erweitert dies die Liste der Gene, durch welche diese Kernrezeptoren den Arzneimittel-Metabolismus beeinflussen und potenziell zu Arzneimittelwechsel-wirkungen beitragen. Die erhaltenen Daten konkretisieren darüber hinaus die Funktion von PPARa als Regulator von DMET-Genen in vitro, beispielsweise durch eine Erhöhung der Expression von CYPs 3 A 4, 2 B 6, 2 C 8 und UGT 1 A 1. Dies lässt auch auf eine Beteiligung von PPARa bei Arzneimittelnebenwirkungen in vivo schließen. Des Weiteren zeigten die Analysen, dass Gene, wie beispielsweise Pyruvat Dehydrogenase Kinase 4 (PDK 4), Glycogen Synthase 2 (GYS 2) und <b>Carnitin</b> Palmitoyltransferase 2 (CPT 2), deren Proteine an der Energiehomöostase beteiligt sind, in Folge einer PXR Aktivierung differenziell exprimiert wurden. Ein solcher Zusammenhang war für diese Gene bisher unbekannt. Diese Resultate erweitern die bestehenden Kenntnisse der potenziellen Mechanismen über die PXR Stoffwechselprozesse wie Fettsäure-Abbau, Glukoneogenese und de novo Lipogenese beeinflusst und somit PXR zu Veränderungen von Lipid- und Glukose-Spiegeln oder Erkrankungen wie hepatischer Steatose beitragen kann. Neben einer Liganden-abhängigen Regulation von Kernrezeptoren wurde auch für post-translationale Modifikationen gezeigt, dass diese Einfluss auf die Aktivität von Kernrezeptoren und deren Zielgen-Expression nehmen. So wurde für die Proteinkinase A (PKA) eine Repression der CPY 3 A 4 Expression, als Folge einer PXR-Phosphorylierung, gezeigt. Ein Einfluss der PKA auf die Expression anderer humaner DMET-Gene hingegen ist bislang kaum untersucht. Der zweite Teil dieser Arbeit beschäftigte sich daher mit der Untersuchung des Einflusses einer PKA-Aktivierung auf die Expression und Aktivität von Arzneimittel-metabolisierenden Enzymen, in Abhängigkeit von PXR und dessen nächstverwandtem Kernrezeptor CAR. In dieser Arbeit wurde durch qRT-PCR Analysen der mRNA-Expression und CYP-Aktivitätsmessungen, mittels eines Cocktail-Assays, in primären humanen Hepatozyten gezeigt, dass eine PKA-Aktivierung durch 8 -bromo cAMP eine Determinante des Arzneimittelstoffwechsels in vitro darstellt. Diese Analysen zeigten eine Repression der CAR und PXR vermittelten, sowie der basalen Expression und Aktivität von CYP 1 A 1, CYP 2 B 6, CYP 2 C 8 und CYP 3 A 4 als auch der Expression von ATP-binding cassette Transporter B 1 (ABCB 1) und UGT 1 A 1. Reporter-Gen Experimente zeigten zudem, dass die beobachteten Effekte in Verbindung mit einer erniedrigten PXR- und CAR-Aktivität standen. Des Weiteren wurde aufgezeigt, dass die Expression von DMET-Genen auch durch das Hormon Glucagon, ein physiologisch relevanter Aktivator des PKA-Signalweges, reprimiert wurde, was bisher in dieser Form noch nicht untersucht worden war. Auf Grund der breiten Liganden-Spezifität von PXR führen Behandlungen mit Arzneimitteln, sowie mit sogenannt „natürlichen“ Heilmitteln wie Johanniskraut, oft zu einer unerwünschten PXR-Aktivierung. Diese PXR-Aktivierung und die dadurch hervorgerufene veränderte Expression und Aktivität von DMET stehen im Zusammenhang mit einer Vielzahl von Arzneimittelnebenwirkungen. Solche Arzneimittelnebenwirkungen sind auch für Johanniskraut-Präparate beschrieben, die auf den potenten PXR-Agonisten Hyperforin zurückzuführen sind. Hyperforin, die stärkste aktive Komponente der Johanniskrautpflanze, welche zur Behandlung von Depressionen verwendet wird, vermittelt seine antidepressive Wirkung über eine selektive Aktivierung des TRPC 6 -Kanals und in Folge dessen eine Inhibierung der Serotonin-Wiederaufnahme. Zur Vermeidung solcher Arzneistoffnebenwirkungen wäre es daher von großem Vorteil, wenn bei der Arzneimittelentwicklung Strategien zur Verfügung ständen, mit denen man eine PXR-Aktivierung verhindern könnte, ohne den pharmakologischen Effekt zu beeinträchtigen. Als Beispiel für eine solche Strategie wurde im letzten Teil dieser Arbeit eine in vitro Studie durchgeführt, um synthetische, acylierte Phloroglucinole, welche als Ersatzstoffe für Hyperforin entwickelt wurden, auf ihr PXR-Aktivierungspotential im Vergleich zu Hyperforin und Rifampicin, hin zu untersuchen. Eine frühere in vitro Studie konnte bereits zeigen, dass fünf dieser synthetischen acylierten Phloroglucinole einen mit Hyperforin vergleichbaren pharmakologischen Effekt besitzen. Eine Hyperforin- und Rifampicin-Behandlung von HepG 2 Zellen, die mit einem Expressions-Vektor für humanes PXR, sowie einem CYP 3 A 4 -Reporter-Konstrukt transfiziert waren, resultierte in einer potenten PXR-abhängigen Induktion des CYP 3 A 4 -Promotors, während die TRPC 6 -aktivierenden Substanzen keine PXR-Aktivierung und CYP 3 A 4 -Promotor Induktion zeigten. Die Behandlung von primären humanen Hepatozyten mit Hyperforin und Rifampicin führte zu einer stark korrelierenden Induktion von PXR-Zielgenen; die Behandlung mit den Phloroglucinol-Derivaten hingegen rief nur moderate Expressions-Änderungen hervor, welche nur schwach mit den durch Rifampicin-Behandlung vermittelten Effekten korrelierten. Das in dieser in vitro Studie beobachtete Fehlen einer PXR-Aktivierung durch die TRPC 6 -aktivierenden Phloroglucinole wurde weiter unterstützt durch die im Rahmen einer Kooperation von Prof. Ekins durchgeführten in silico Pharmakophor-Modellierungen und Bindungsstudien, die nur schwache Interaktionen der TRPC 6 -aktivierenden Derivate mit PXR vorhersagten (Kandel et al., 2014). Diese Herangehensweise zeigte, dass Strategien mit dem Ziel, eine PXR-Aktivierung zu untersuchen und diese zu vermeiden, einen denkbaren Ansatz bieten, um in der Arzneimittelentwicklung dem Auftreten von Arzneimittelwechselwirkungen vorzubeugen und damit die Sicherheit von Medikamenten zu verbessern. Zusammenfassend lässt sich sagen, dass in der hier präsentierten genomweiten Studie an humanen Hepatozyten zahlreiche neue Zielgene der NRs CAR, PXR und PPARa identifiziert wurden, welche zu einer Beeinflussung des Arzneimittelstoffwechsels und der Energiehomöostase durch diese NRs beitragen könnten. Darüber hinaus wurde gezeigt, dass die PKA, die unter anderem die Effekte des Hormons Glucagon vermittelt, eine Einflussgröße für die Arzneimittelentgiftung im Menschen darstellt. Des Weiteren wurde am Beispiel von Hyperforin-Derivaten eine Strategie präsentiert, die zur Untersuchung und Vermeidung von Arzneimittel-interaktionen in der Medikamentenentwicklung beitragen kann. Im Hinblick auf die personalisierte Medizin und die allgegenwärtige Polypharmazie werden solche Informationen in Zukunft unerlässlich sein, um Probleme, die durch intra- und interindividuelle Variabilität hervorgerufen werden, zu berücksichtigen und um das Auftreten von Therapieversagen und Arzneimittelwechselwirkungen zu minimieren...|$|E

